Microsoft vs Twist Bioscience Corp — how do they compare? Microsoft trades at $396.88 (market cap $2.99T), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Microsoft is far larger — about 548.6× Twist Bioscience Corp's market cap, and Microsoft pays a 0.9% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| MSFT | TWST | |
|---|---|---|
Market Cap | $2.99T | $5.45B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $102.88 |
52-Week Low | $352.83 | $24.16 |
Enterprise Value | $2.97T | $5.37B |
Dividend Yield | 0.9% | — |
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $397.75, up 1.0% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $281.72B in 2025, with net income of $101.83B, and the company has beaten EPS estimates for three consecutive quarters. Analysts maintain an 80.49% buy rating with a consensus price target of $546.70, highlighting AI leadership through Azure and Copilot.
The outlook remains positive given robust earnings growth and AI-driven opportunities, but risks include elevated capital expenditure concerns and competitive pressures. Valuation metrics like a P/E of 23.96 and P/S of 9.43 suggest the stock is fairly priced, supporting a long-term bullish view tempered by near-term volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →